381 completed, 40 unknown, 30 terminated, 13 withdrawn. 142 Phase 3, 134 Phase 4, 76 Phase 2, 69 Phase 1, 51 Not applicable.
Follow this drug Literature Review of Sitagliptin Phosphate trials Research Report on Sitagliptin Phosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease Sitagliptin, Sitagliptin placebo - Parkinson Disease | Phase 2 | Not yet recruiting | Yonsei University | 160 | 2026-12-15 | 2026-09-10 |
| iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD) N0892, Januvia® + Glifage XR® + Placebo, Forxiga® + Glifage XR® + Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-11-30 | 2025-12-18 | |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT Post transplant cyclophosphamide, bortezomib and sitagliptin in 3+3 design to MTD - GVHD - Graft-Versus-Host Disease | Phase 1 / Phase 2 | Not yet recruiting | Northwell Health | 72 | 2026-07-01 | 2026-06-30 |
| Sitagliptin in Recurrent/Progressive Grade 4 Glioma Sitagliptin, Bevacizumab - Glioma, Glioblastoma | Phase 1 | Recruiting | Kailin Yang, MD, PhD | 45 | 2026-06-11 | 2026-06-17 |
| Sitagliptin With Pembro in RCC and Melanoma Sitagliptin, Pembrolizumab - Advanced Renal Cell Carcinoma, Advanced Melanoma | Phase 1 | Recruiting | Fernando Maciel Barbosa | 64 | 2026-05-14 | 2026-07-30 |
| A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults. ABBV-722, Midazolam, Metformin - Healthy Volunteers | Phase 1 | Completed | AbbVie | 12 | 2026-04-30 | 2026-08-20 |
| Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC Oxaliplatin, Capecitabine, Anti-PD-1 monoclonal antibody - Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 138 | 2026-04-09 | 2026-05-13 |
| A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas Sitagliptin - Glioblastoma, Brain Tumor | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 48 | 2026-03-16 | 2026-08-06 |
| Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data. Dulaglutide, Sitagliptin - Type 2 Diabetes | Completed | Brigham and Women's Hospital | 300000 | 2026-02-03 | 2026-07-10 | |
| Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm) - Breast Cancer | Phase 4 | Recruiting | Tanta University | 150 | 2026-02-01 | 2026-10-15 |
| INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) Dulaglutide, Semaglutide, Tirzepatide - Type 2 Diabetes, Overweight | Completed | Brigham and Women's Hospital | 60000 | 2026-01-27 | 2026-07-09 | |
| Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL) Oral semaglutide, Sitagliptin - Type 2 Diabetes, Heart Failure | Completed | Brigham and Women's Hospital | 25664 | 2026-01-24 | 2026-09-21 | |
| Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes Metformin+ Empagliflozin + Sitagliptin, Metformin + Empagliflozin + Linagliptin - Type 2 Diabetes Mellitus | Phase 4 | Enrolling by invitation | Bahria University | 110 | 2026-01-01 | 2026-03-05 |
| Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study. Janumet XR, Sitagliptin/Metformin FDC - Bioequivalance | Not applicable | Completed | ADIUM | 46 | 2025-12-08 | 2026-08-14 |
| Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fast Study. Janumet XR, Sitagliptin/Metformin FDC - Bioequivalance | Not applicable | Completed | ADIUM | 46 | 2025-12-03 | 2026-08-14 |
| Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fed Study. Janumet XR, Sitagliptin/Metformin FDC - Bioequivalence | Not applicable | Completed | ADIUM | 46 | 2025-11-24 | 2026-08-14 |
| Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study. Sitagliptin/Metformin FDC, Janumet XR - Bioequivalance | Not applicable | Completed | ADIUM | 46 | 2025-11-19 | 2026-08-14 |
| Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors Sitagliptin 100 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg, Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg - Diabetes Mellitus, Type 2, Hyperglycemia | Phase 4 | Not yet recruiting | Yonsei University | 100 | 2025-09-01 | 2025-08-07 |
| Comparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients Trelagliptin 100 mg, Sitagliptin 100mg OD - Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus | Phase 3 | Enrolling by invitation | Khyber Medical College, Peshawar | 126 | 2025-07-01 | 2025-07-18 |
Showing 20 of 485. Sign in to see all of them.
Diabetes Mellitus, Type 2 (334) · Diabetes Mellitus (93) · Diabetes Mellitus, Type 1 (17) · Insulin Resistance (14) · Hyperglycemia (10) · Glucose Intolerance (9) · Obesity (9) · Inflammation (7) · Non-alcoholic Fatty Liver Disease (7) · Heart Failure (6) · Prediabetic State (6) · Hypertension (5) · Hypoglycemia (5) · Polycystic Ovary Syndrome (5) · Atherosclerosis (4)
Merck Sharp & Dohme LLC (91) · AstraZeneca (13) · Novo Nordisk A/S (13) · Brigham and Women's Hospital (11) · GlaxoSmithKline (8) · Boehringer Ingelheim (7) · Emory University (7) · Novartis Pharmaceuticals (7) · Galenicum Health (6) · Vanderbilt University (6) · Eli Lilly and Company (5) · Janssen Research & Development, LLC (5) · Sanofi (5) · University Hospital, Gentofte, Copenhagen (5) · ADIUM (4)
United States (153) · South Korea (46) · Germany (39) · Canada (37) · China (36) · Mexico (35) · India (31) · Japan (20) · United Kingdom (20) · Spain (19) · France (18) · Brazil (17) · Poland (17) · Hungary (16) · Romania (16)
Shirley Wang, PhD, ScM (10) · Guillermo Umpierrez, MD (4)
PMID 26580237, PMID 27977934, PMID 31797522, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 32998732, PMID 24517339, PMID 24742013, PMID 24786834, PMID 24918789, PMID 25329038, PMID 25633134, PMID 25813214, PMID 26121561, PMID 26373629, PMID 26579834, PMID 27600862, PMID 28197834, PMID 28241822, PMID 28327140, PMID 31903692, PMID 32306296, PMID 32700393, PMID 35472672, PMID 38770818, PMID 17622601, PMID 21235696, PMID 22405352, PMID 23522121, PMID 23748506, PMID 23748507, PMID 24432999, PMID 24585202, PMID 24699248, PMID 25795432, PMID 27391951, PMID 27964837, PMID 29313267, PMID 30880443, PMID 32267058, PMID 32362346, PMID 33660198, PMID 34033212, PMID 34213819, PMID 35373893, PMID 36526947, PMID 37178435, PMID 37435938
2015 (7), 2008 (6), 2014 (4), 2009 (2), 2018 (2), K23HL119602 (2), 2019 (1), 2025 (1), R01DK097554 (1), R01DK108643 (1), R01HL112669 (1), R03DK084089 (1), U01DK098246 (1), U54RR014616 (1), UM1AI068636 (1)